Virbac Shares Climb to €369, TP Icap Raises Target to €412
Midday sees the Carros veterinary laboratory up by 2.5% at €369 in a well-oriented Parisian market. The SBF 120 concurrently rises by 0.41%. The stock is among the top gainers in the broad index.
TP Icap Midcap Raises Target to €412 and Reaffirms Buy Recommendation
On May 21, TP Icap Midcap raised its price target on Virbac from €407 to €412, while maintaining its buy opinion. Based on the current price of €369, this new target implies a potential upside of nearly 11.7%. This revision follows the stock's 8.21% recovery over the week and a year-to-date gain of 18.08%. The session's rebound extends the movement that began after defending the moving average, in a previous session where the stock gained 2.75% to €355.
Price Moves Above Its Three Moving Averages, Targeting €384 Resistance
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
At €369, the stock is now trading above its three moving averages: MM20 at €361.75, MM50 at €356.68, and MM200 at €347.37, marking a 6.23% increase from the latter. This setup confirms the exit from the consolidation phase observed at the beginning of May. The RSI at 51 remains neutral, allowing room for growth before any overbought signal. The next identified level in the data is the €384 resistance, about 4% from the current price. The one-month volatility is measured at 7.40%. The stock maintains a positive momentum over the last three months, slightly up (+0.14%), but bolstered by the recent session rebounds.
SectorPharmacie et biotechnologies›Vaccins et laboratoires de recherche
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 768 millions d'euros
Quarterly revenue: 768 millions d'euros
Guidance from the release
notre forte dynamique du premier semestre (+7,4 % de croissance) nous permet de viser la borne haute de notre fourchette
Outlook / guidance
Expected revenue: 1 575 millions d'euros
Management commentary: la borne haute de notre fourchette initiale de croissance du chiffre d'affaires (comprise entre 5,5 % et 7,5 % à PCC) et une marge de résultat opérationnel courant ajusté d'environ 17 % à PCC
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
